Ascendiant Capital raises Lucid Diagnostics target to $9.50
Ascendiant Capital raised its Lucid Diagnostics price target to $9.50 per share from $9.25.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.